Following the establishment of histone deacetylases (HDACs) as promising therapeutic targets for the reversal of aberrant epigenetic states associated with cancer, the development of HDAC inhibitors (HDACi) and their underlying mechanisms of action has been a significant area of scientific interest. HDACi induce diverse biological responses including the inhibition of cell proliferation by blocking progression through the G1 or G2/M phases of the cell cycle. As a putative tumor-suppressor protein, p21
INTRODUCTION
Histone deacetylase (HDAC) inhibitors (HDACi) have been successfully used to treat patients with hemopoietic malignancies, although the molecular and biological events that underlie their therapeutic effects have not been clearly delineated. 1 HDACi induce a range of tumor cell intrinsic biological outcomes such as induction of cell cycle arrest, senescence, apoptosis and differentiation, any one or more of which may have a primary role in reducing tumor burden. 1 Interestingly, HDACi can concurrently induce both cell cycle arrest and apoptosis, 2 and inhibition of apoptosis through forced expression of pro-survival Bcl-2 proteins results in HDACi-mediated cell cycle arrest, becoming the dominant biological outcome. 3, 4 Although we have demonstrated that induction of tumor cell apoptosis is requisite for diverse HDACi such as vorinostat, panobinostat and romidepsin to mediate significant therapeutic benefit in pre-clinical models, [4] [5] [6] it remains possible that the interplay between inhibition of the cell cycle and initiation of apoptosis ultimately determines the relative sensitivity of tumor cells to HDACi-induced death. Indeed, overexpression of p21 waf1/cip1 can confer resistance to HDACimediated apoptosis 7 providing some evidence that cell cycle regulatory proteins may influence the sensitivity of tumor cells to HDACi-mediated apoptosis.
HDACi can affect the cell cycle by up-and/or downregulating the expression of a number of cell cycle proteins including the cyclin-dependent kinase inhibitors (CDKi) p21 waf1/cip1 , p27 Kip1 and p57 Kip2 , and cyclins A and D. 8 Both p57 Kip2 and p27 Kip1 have been reported to have tumor-suppressor functions, 9, 10 however, a similar role for p21 waf1/cip1 remains controversial. 11 Deletion of cdkn1a in mice can result in spontaneous tumors with late onset, 12 whereas Ras-induced transformation of keratinocytes from cdkn1a knockout mice resulted in an increase in proliferation and a downregulation of the differentiation markers compared with effects in wild-type keratinocytes. 13 Conversely, other studies using a model of tumorigenesis mediated by infection of newborn mice with Moloney murine leukemia virus showed that knockout of cdkn1b encoding p27 Kip1 but not cdkn1a increased tumor onset. 14 As a consequence of altering cyclin-CDK activity, treatment of tumor cells with HDACi can result in cell cycle arrest at the G1/S checkpoint concomitant with the dephosphorylation of retinoblastoma protein (pRb). 1 Interestingly, HDACi can induce expression of p21 waf1/cip1 in a p53-independent manner, 15 and it has been proposed that p21 waf1/cip1 can influence the decision of a tumor cell to undergo apoptosis and/or cell cycle arrest following HDACi treatment. For example, overexpression of p21 waf1/cip1 can confer resistance to HDACi-mediated apoptosis, 7 however, the effects of HDACi on tumor cell apoptosis in the absence of p21 waf1/cip1 are inconsistent. For example, while one study reported the loss of p21 waf1/cip1 -abolished butyrate-induced G1 arrest, 16 another study reported that Trichostatin A (TSA) was still able to induce a G1 arrest in human colon HCT116 cells deficient of p21 waf1/cip1 . 17 Thus, in this study, Em-myc transgenic mice were crossed with cdkn1a knockout mice to determine the role of p21 waf1/cip1 in regulating myc-induced lymphomagenesis. The Em-myc lymphomas derived from that experiment were assessed for their sensitivity to vorinostat-mediated apoptosis and cell cycle arrest. Our results indicate that p21 waf1/cip1 does not have a major role in regulating the oncogenic activities of c-myc nor is it important for vorinostat-induced apoptosis or cell cycle arrest.
RESULTS
Deletion of cdkn1a does not increase the rate of tumorigenesis in Em-myc transgenic mice To determine the role of p21 waf1/cip1 in regulating myc-induced tumorigenesis, cdkn1a À / À mice were crossed with Em-myc transgenic mice, 18 and subsequent intercrossing was performed to establish Em-myc
À / À colonies. As shown in Figure 1a , mice that did not express the myc transgene but had deletion of cdkn1a did not develop lymphoma nor did they display any signs of illness throughout the 400-day study period. Conversely, mice harboring the c-myc transgene that were wild type for cdkn1a developed lymphoma with kinetics consistent with previously published Em-myc mouse studies. 18 Homozygous deletion of cdkn1a on an 
/cdkn1a
À / À mice were negative for p21 waf1/cip1 expression in the presence and absence of vorinostat treatment (Figure 1b) .
Knockout of p21
waf1/cip1 does not affect the sensitivity of the lymphoma cells to vorinostat Tumor cells overexpressing p21 waf1/cip1 can have reduced sensitivity to HDACi-induced apoptosis. 7 We therefore determined whether Em-myc lymphomas deficient in p21 waf1/cip1 were hypersensitive to HDACi-induced apoptosis. Lymphomas from Em-myc
À / À mice were tested for their sensitivity to vorinostat-induced apoptosis, and as shown in Figure 1 . Homozygous deletion of cdkn1a on an Em-myc background does not increase tumorgenesis. (a) Em-myc transgenic mice were crossed with cdkn1a knockout mice, and the resulting genotypes (Em-myc
were compared in a survival study from 2 weeks of age. A minimum of 15 mice per genotype were entered into the study and mice were genotyped at the beginning and at the end of the study to verify their genotypic status. The study was terminated at 400 days, Kaplan-Meier analysis was performed and comparisons were made using the log-rank (Mantel-Cox) test (MedCalc software Version 8.0.2.0). (b) Lymph nodes were harvested from Em-myc/cdkn1a
þ / þ and Em-myc/cdkn1a À / À mice and cultured in vitro. Cells were tested by western blot for the presence of p21 waf1/cip1 expression following exposure to 2 mM vorinostat for 6 h. Cells obtained from Em-myc/cdkn1a þ / þ mice are highlighted in red. þ / þ and Em-myc/cdkn1a À / À tumors. Consistent with previous studies that showed treatment of mice bearing Em-myc lymphomas with vorinostat significantly increased their life span, 4 the survival of vorinostat-treated mice used in this study was also significantly extended compared with vehicle-treated mice irrespective of the cdkn1a status of the tumors (Figures 3a-e, Table 1 ). Taken together, our results indicated that although cdkn1a was an HDACi-responsive gene, loss of expression of p21 waf1/cip1 did not affect the apoptotic or therapeutic effects of vorinostat.
HDACi-induced cell cycle arrest still occurs in the absence of p21
We have previously shown that cells resistant to vorinostatinduced apoptosis through overexpression of the pro-survival protein, Bcl-2, undergo arrest at the G1 phase of the cell cycle. 4 To determine the importance of p21 waf1/cip1 in mediating this cell cycle arrest, we overexpressed Bcl-2 in Em-myc/cdkn1a
þ / þ and Em-myc/cdkn1a
À / À cells ( Figure 4a ). Em-myc/cdkn1a þ / þ /Bcl-2 and Em-myc/cdkn1a
À / À /Bcl-2 cells had equivalent levels of overexpressed Bcl-2, and p21 waf1/cip1 was induced by vorinostat in Em-myc/cdkn1a
þ / þ /Bcl-2 cells (Figure 4a ). The anti-apoptotic activity of Bcl-2 was confirmed by exposing the cells to vorinostat and measuring uptake of propidium iodide (PI) as a readout for cell viability. As shown in Figure 4b , Em-myc/cdkn1a
þ / þ /Bcl-2 and Em-myc/cdkn1a
À / À /Bcl-2 cells were resistant to vorinostatinduced apoptosis, whereas Em-myc/cdkn1a
þ / þ and Em-myc/ cdkn1a -/ cells were equivalently sensitive to vorinostat. The cell cycle profiles of Em-myc/cdkn1a
þ / þ /Bcl-2 and Em-myc/ cdkn1a
À / À /Bcl-2 cells grown in the presence and absence of vorinostat were analyzed ( Figure 4c ). As expected, knockout of cdkn1a resulted in the cells proliferating slightly faster than Em-myc tumors wild type for cdkn1a (unpublished observations), and this was reflected by the relatively greater proportion of Em-myc/cdkn1a À / À /Bcl-2 cells in S-phase compared with Em-myc/cdkn1a
þ / þ /Bcl-2 cells. Treatment with vorinostat, however, induced a reduction in the proportion of cells in S-and G2/M phases of the cell cycle and an increase in cells in G1 that was not dependent on the presence of wild-type cdkn1a (Figure 4c ). The vorinostat-induced cell cycle arrest at the G1/S checkpoint was confirmed biochemically by analysis of the phosphorylation state of Rb. Consistent with the cell cycle data shown in Figure 4c , greater levels of hyperphosphorylated Rb (ppRb) was observed in untreated Em-myc/cdkn1a
À / À /Bcl-2 cells compared with Em-myc/cdkn1a
þ / þ /Bcl-2 cells (Figure 4d ). Treatment with vorinostat resulted in the appearance of hypophosphorylated Rb (pRb) in both Em-myc/cdkn1a
À / À / Bcl-2 and Em-myc/cdkn1a
þ / þ /Bcl-2 cells (Figure 4d ). Taken together, these data demonstrate that vorinostat-induced cell cycle arrest at the G1/S checkpoint still occurs in the absence of p21 waf1/cip1 .
N.S Vorinostat ( M)
Vorinostat ( M) % PI Uptake þ / þ and Em-myc/cdkn1a
À / À lymphomas were incubated in vitro for 24 h with the indicated doses of vorinostat. Cell viability was assessed by: (a) PI staining, and (b) mitochondrial outer membrane permeabilization (MOMP) was determined by TMRE staining. Data shown is the mean of three independent experiments ± s.e.m. Levels of significance were determined by a Student's two-tailed t-test; NS, not significant. Figure 3 . Absence of p21 waf1/cip1 does not affect the therapeutic efficacy of vorinostat in vivo. C57BL/6 mice (10 mice per group) injected with the following Em-myc lymphomas:
À / À (tumor no. 4). Tumor-bearing mice were treated with vorinostat or vehicle (DMSO) after WBC counts reached B13 Â 10 3 /ml. The therapy consisted of 200 mg/kg vorinostat intraperitoneal injections (i.p) daily for 7 days, then 150 mg/kg for 3 weeks or until mice succumbed to disease. Kaplan-Meier analysis was made using the log-rank (Mantel-Cox) test (MedCalc software version 8.0.2.0).
P27
Kip1 has an important role in vorinostat-mediated cell cycle arrest at G1/S but not vorinostat-induced apoptosis HDACi have been reported to upregulate the expression of both p57 kip2 and p27 Kip1 , and induce a G1 cell cycle arrest preceding apoptosis. 20 Thus, we tested for expression of p57 Kip2 and p27
Kip1
in Em-myc/cdkn1a þ / þ /Bcl-2 and Em-myc/cdkn1a À / À /Bcl-2 cells following vorinostat treatment. There was no apparent increase in expression of p57
Kip2 following treatment with vorinostat in either lymphoma ( Figure 5a) ; however, the expression of p27 Kip1 was substantially increased in vorinostat-treated cells (Figure 5b ). To determine whether increased expression of p27
Kip1 following vorinostat treatment occurred at the transcriptional or posttranscriptional level, we assessed the expression of both cdkn1a and cdkn1b mRNA in Em-myc/cdkn1a
À / À /Bcl-2 cells following vorinostat treatment. Consistent with previous reports, 19 cdkn1a mRNA was markedly induced in a time-dependent manner following treatment of Em-myc/ cdkn1a
þ / þ /Bcl-2 cells with vorinostat ( Figure 5c ). In contrast, the levels of cdkn1b mRNA remained relatively unchanged in Em-myc/ cdkn1a
þ / þ /Bcl-2 and Em-myc/cdkn1a À / À /Bcl-2 cells treated with vorinostat (Figure 5d ). These data indicate that the increase in p27
Kip1 expression following vorinostat treatment occurs only at a translational level and is not a transcriptional event.
To determine the potential functional role of p27 Kip1 in response to vorinostat, we targeted cdkn1b in Em-myc/ cdkn1a
À / À cells overexpressing Bcl-2 using RNA interference to knockdown p27 Kip1 . As shown in Figure 6a , cells transduced with miR30-based vectors expressing two different short hairpin RNA (shRNA) sequences targeting cdkn1b (Em-myc/cdkn1a
À / À /shRNAmiR-cdkn1b#1/Bcl-2 and Em-myc/cdkn1a
À / À /shRNAmiR-cdkn1b#2/ Bcl-2) had a dramatic decrease in expression of p27 Kip1 . In contrast, cells transduced with a control miR30 vector with a non-targeting scrambled shRNA sequence (Em-myc/cdkn1a
À / À /shRNAmiR-Scr/ Bcl-2) expressed wild-type levels of p27 Kip1 . These cells were then exposed to vorinostat and cell cycle progression was assessed.
Knockdown of p27
Kip1 in cdkn1a knockout cells resulted in a loss of vorinostat-mediated arrest at the G1/S checkpoint that was observed in p21 waf1/cip1 -competent cells (Figure 6b) . Remarkably, the Em-myc/cdkn1a
À / À /shRNAmiR-cdkn1b/Bcl-2 cells were arrested in G2/M following exposure to vorinostat, indicating that p27 Kip1 has a key role in mediating vorinostat-induced cell cycle arrest at G1/S.
We next determined if knockdown of cdkn1b in cdkn1a-deleted Em-myc cells affected vorinostat-induced apoptosis. As shown in Figures 7a-c , Em-myc lymphomas were equivalently sensitive to vorinostat regardless of p27 kip1 expression. We also tested the importance of p27
Kip1 in regulating the in vivo therapeutic effects of vorinostat using C57B/6 mice mice bearing Em-myc/cdkn1a
tumors. Interestingly, the antitumor efficacy of vorinostat remained fully intact in mice bearing Em-myc tumors with concomitant deletion of cdkn1a and shRNAmiR-mediated þ / þ (tumor no. 1) and Em-myc/ cdkn1a À / À (tumor no. 1) lymphoma cells were retrovirally transduced with MSCV-Bcl-2 or MSCV alone. Tumor cells were incubated for 6 h with or without 2 mM vorinostat. Cells were harvested and analyzed by western blot. Expression of p21 waf1/cip1 and Bcl-2 was measured with anti-mouse p21 antibody and anti-mouse Bcl-2 antibody, respectively. Anti-b-actin was used as a loading control. (b) Lymphomas developed in a were incubated with increasing doses of vorinostat for 24 h. Cell death was analyzed by PI staining and data shown is the mean of three independent experiments ±s.e.m. Levels of significance were determined by a Student's two-tailed t-test; **Po0.01. (c) Em-myc/ cdkn1a þ / þ /Bcl-2 and Em-myc/cdkn1a À / À /Bcl-2 lymphoma cells were cultured with or without 0.5 mM vorinostat for 24 h. Cell cycle status was determined by PI staining. The percentage of cells in G1, S and G2/M phases of the cell cycle are shown and SubG1 was not measured. Data shown is the mean of three independent experiments ±s.e.m. Levels of significance were determined by a Student's two-tailed t-test; *Po0.05 for the percentage decrease of cells in S-phase. (d) Mouse Rb expression in Em-myc/cdkn1a
À / À /Bcl-2 lymphoma cells was detected by western blot following a 24-h incubation in vitro with 2 mM vorinostat. Anti-bactin antibody was used as a loading control.
Regulation of HDACi antitumor activity
A Newbold et al depletion of cdkn1b (Figure 7d , Table 1 ). Our results therefore indicated that while both cdkn1a and cdkn1b were HDACiresponsive genes, the loss of expression of p21 waf1/cip1 or p27 kip1 , individually or combined, did not affect the apoptotic or therapeutic effects of vorinostat.
As mentioned previously in Figure 6b , the p21/p27 doubledeficient cells were arrested in G2/M following exposure to vorinostat, indicating that p27
Kip1 had a key role in mediating vorinostat-induced cell cycle arrest at G1/S. We therefore assessed the phosphorylation status of Rb in Em-myc tumors with deletion of cdkn1a and shRNAmiR-mediated depletion of cdkn1b following treatment with vorinostat. As shown in Figure 7e , vorinostat treatment resulted in Rb hypophosphorylation regardless of the expression status of p21 waf1/cip1 or p27 kip1 .
DISCUSSION
In this study, we determined whether the loss of cdkn1a affected the rate of lymphomageneis in the Em-myc mouse, and by using Em-myc/cdkn1a À / À tumor cells, we determined whether loss of cdkn1a affected vorinostat-mediated apoptosis or cell cycle arrest. Homozygous deletion of cdkn1a in C57BL/6 mice did not result in spontaneous tumor development. Our results are in contrast to the study by Martín-Caballero et al., 12 who reported that cdkn1a -/-mice developed spontaneous tumors with a late onset of around 16 months. One explanation could be difference in genetic backgrounds of the cdkn1a À / À mice with the mice used in our study being on a pure C57BL/6 background, whereas the Martín-Caballero study used mice on a mixed 129Sv/C57BL/6 background. We also demonstrated that deletion of cdkn1a did not accelerate myc-induced tumorigenesis and these studies align with others demonstrating that loss of cdkn1a alone did not affect tumor development driven by Moloney murine leukemia virus infection. 14 In a previous study, deletion of cdkn1a enhanced the rate of tumorigenesis only in the context of loss of one allele of cdkn1b, 14 demonstrating a level of functional redundancy between different CDKi that we hypothesize may also be apparent in vorinostatmediated cell cycle arrest as discussed below.
It has been well documented that transcriptional induction of cdkn1a resulting in increased expression of p21 waf1/cip1 is a common molecular response to treatment of cells with HDACi; 1 however, the importance of p21 waf1/cip1 in regulating HDACiinduced apoptosis or cell cycle arrest remains controversial. Although some studies have proposed that HDACi-mediated upregulation of p21 waf1/cip1 has an essential role in subsequent cell cycle arrest at the G1/S transition 1 and may either protect cells from HDACi-mediated apoptosis 7, 21 or promote the apoptotic effects of HDACi, 22 we saw no such effects using Em-myc/cdkn1a À / À tumors. Our results are supported by other studies demonstrating that knockdown of cdkn1a in colon carcinoma lines did not sensitize cells to death following treatment with a vorinostat/bortezomib combination. 23 Moreover, the HDACi trichostatin A induced equivalent cell cycle arrest in human isogenic CDKN1A þ / þ and CDKN1A À / À cell lines produced by homologous recombination. 17 All previous studies performed to date that aimed to determine the functional role of CDKN1A/cdkn1a in mediating biological responses to HDACi were performed using tumor cell lines grown in culture. A key component of our study were in vivo experiments using primary lymphomas to determine whether the loss of cdkn1a altered the therapeutic effects of vorinostat in a physiologically relevant setting. As shown in Figure 3 , deletion of cdkn1a had little or no effect on the ability of vorinostat to mediate therapeutic responses as measured by increased survival of mice bearing Em-myc lymphomas. Using the Em-myc system, we have clearly demonstrated that induction of tumor cell apoptosis is key for different HDACi to provide therapeutic benefit. 4, 5, 6 Moreover, using the same system, we have recently shown that HDACi with broad HDAC specificity (for example, vorinostat) and agents that predominantly inhibited selected class I HDACs (for example, romidepsin) mediate effects on tumor cell proliferation and survival in vitro and in vivo. 24 Our studies using Em-myc/ cdkn1a À / À tumors clearly showed that even though p21
was robustly induced by vorinostat in Em-myc cells, it did not have an important role in regulating vorinostat-induced apoptosis in vitro or therapeutic efficacy in vivo. Interestingly, when we blocked vorinostat-mediated apoptosis in Em-myc cells through overexpression of Bcl-2, the cells went into cell cycle arrest at the G1/S transition that was not dependent on p21 waf1/cip1 . We note that in other tumor settings driven by oncogenic proteins and þ / þ /Bcl-2 versus Em-myc/cdkn1a À / À / Bcl-2 lymphoma cells was detected by western blot following a 6-h incubation in vitro with 2 mM vorinostat. Anti-b-actin antibody was used as a loading control. All westerns are a representative of at least four independent experiments. (c, d) The levels of cdkn1a and cdkn1b mRNA following vorinostat treatment were measured by quantitative real-time PCR in Em-myc/cdkn1a
À / À /Bcl-2 lymphoma cells after incubation with 2 mM vorinostat. Time points were taken at 2, 4 and 6 h, and RNA and cDNA were made according to standard methods (refer to Materials and methods for details). Fold change in (c) cdkn1a mRNA or (d) cdkn1b mRNA levels normalized to HPRT mRNA levels are shown. Data shown represents mean of three independent experiments ±s.e.m. Levels of significance were determined by a Student's two-tailed t-test; *Po0.05.
pathways other than Myc, upregulation of cdkn1a and other CDKi may regulate the cellular responses to HDAC inhibition. Moreover, the Em-myc model requires secondary genetic 'hits' that co-operate with c-Myc to drive B-cell transformation. 25 Although we functionally assessed the role of p21 waf1/cip1 in HDACi-induced apoptosis and cell cycle arrest in multiple primary Em-myc tumors, we cannot rule out the possibility that in certain genetic settings, cdkn1a may have a role in mediating antitumor responses mediated by HDACi.
We observed a strong upregulation of p27 kip1 but not p57 kip2 in vorinostat-treated Em-myc/cdkn1a þ / þ /Bcl-2 and Em-myc/ cdkn1a
À / À /Bcl-2 cells, indicating that p27 kip1 may provide a level of functional redundancy for loss of cdkn1a. The increased expression of p27 kip1 following vorinostat treatment occurred in the absence of an increase in cdkn1b mRNA pointing to a posttranslational effect. Consistent with our data, it was recently shown that vorinostat increased the expression of p27 kip1 through downregulation of S-phase kinase-associated protein 2 (Skp2) and CDK subunit 1 (Cks1), the components of the SCFSkp2-Cks1 ubiquitin ligase complex. 26 To address the role of p27 kip1 in mediating vorinostat-induced cell cycle arrest, we knocked down cdkn1b in cdkn1a knockout cells. Consistent with the notion that p21 waf1/cip1 and p27 kip1 share functionally redundant roles in regulating transition through G1/S, we found that vorinostattreated cells passed through the G1/S checkpoint but halted in G2/M. These data demonstrate that p27 kip1 is essential for vorinostat-mediated cell cycle arrest at G1/S, but other cell cycle regulatory proteins other than p21 waf1/cip1 and p27 kip1 are important for arrest at later stages of the cell cycle.
In conclusion, we have shown that loss of cdkn1a did not accelerate tumorigenesis in the Em-myc transgenic mouse model. Furthermore, we found that although p21 waf1/cip1 was robustly induced in response to vorinostat, it had little if any role in the apoptotic-or cell cycle regulatory activities of the compound, and loss of cdkn1a did not affect the therapeutic response to vorinostat. Finally, we demonstrate that p27 kip1 , a CDKi that is most likely posttranscriptionally upregulated by vorinostat, has a fundamental role in mediating vorinostat-induced cell cycle arrest at G1/S. 
À / À /shRNAmiR-cdkn1b#1/Bcl-2 and Em-myc/cdkn1a À / À /shRNAmiR-cdkn1b#2/Bcl-2 cells were treated with vehicle of vorinostat (2 mM) for 24 h. Cell cycle analysis was performed using PI staining and the percentage of cells in SubG1, G1, S and G2/M phases of the cell cycle are shown. The profiles shown are a representative of three independent assays.' À / À , Em-myc/cdkn1a À / À /shRNAmiR-Scr and Em-myc/cdkn1a À / À / shRNAmiR-cdkn1b#1 lymphomas were incubated in vitro for 24 h with the indicated doses of vorinostat. Cell viability was assessed by: (b) PI staining, and (c) mitochondrial outer membrane permeabilization (MOMP) was determined by TMRE staining. Data shown is the mean of three independent experiments ± s.e.m. Levels of significance were determined by a Student's two-tailed t-test; NS, not significant. (d) C57BL/6 mice (12 mice per group) were injected intra-venously (i.v.) with Em-myc/cdkn1a À / À , Em-myc/cdkn1a À / À /shRNAmiR-Scr or Em-myc/cdkn1a À / À /shRNAmiR-cdkn1b#1 lymphomas. Tumor-bearing mice were treated with vorinostat or vehicle (DMSO) after WBC counts reached B13 Â 10 3 /ml. Therapy consisted of 200 mg/kg vorinostat i.p daily for 7 days, then 150 mg/kg for 3 weeks or until mice succumbed to disease. Kaplan-Meier analysis was made using the log-rank (Mantel-Cox) test (MedCalc software version 8.0.2.0). (e) Mouse Rb expression in Em-myc/cdkn1a À / À , Em-myc/cdkn1a À / À /shRNAmiRScr, Em-myc/cdkn1a
À / À /shRNAmiR-cdkn1b#1 and Em-myc/cdkn1a À / À /shRNAmiR-cdkn1b#2 lymphoma cells was detected by western blot following a 24-h incubation in vitro with 2 mM vorinostat. Anti-b-actin antibody was used as a loading control.
MATERIALS AND METHODS Mice
Em-myc transgenic male mice were crossed with cdkn1a À / À female mice to produce Em-myc genotype were entered into a survival study from 2 weeks of age. Mice were genotyped at the beginning and end of the study to verify their genotypic status. Mice were palpated every 2-4 days for enlarged nodes, white blood cell counts were monitored fortnightly (Advia 120 Hematology Analyzer, Siemans, Melbourne, VIC, Australia) and the overall health of the mice was monitored daily. When an ethical endpoint was reached, final spleen weights and white blood cell counts were taken along with a necropsy report. 
